Interleukin-4 stimulated T lymphocyte cell death for the treatment of allergic disorders
US5935575A · kind A · utility
5Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 30, 1994 |
| Grant date | Aug 10, 1999 |
| Priority date | — |
| Expiry date | Nov 30, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/868
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention discloses a method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders and graft rejection. Specifically, it provides a means of killing a specific sub-population of T lymphocytes while leaving the majority of other T lymphocytes in the population unaffected. The sub-population of T lymphocytes are killed by repeatedly challenging the population with an antigen in conjunction with administration of interleukin-4.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.